{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:25:36Z","timestamp":1794407136483,"version":"4.9.0"},"reference-count":88,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma (T-ALL\/LBL) is a rare hematologic malignancy most commonly affecting adolescent and young adult males. Outcomes are dismal for patients who relapse, thus, improvement in treatment is needed. Nelarabine, a prodrug of the deoxyguanosine analog 9-\u03b2-arabinofuranosylguanine, is uniquely toxic to T lymphoblasts, compared with B lymphoblasts and normal lymphocytes, and has been developed for the treatment of T-ALL\/LBL. Based on phase 1 and 2 trials in children and adults, single-agent nelarabine is approved for treatment of patients with relapsed or refractory T-ALL\/LBL, with the major adverse effect being central and peripheral neurotoxicity. Since its approval in 2005, nelarabine has been studied in combination with other chemotherapy agents for relapsed disease and is also being studied as a component of initial treatment in pediatric and adult patients. Here, we review current data on nelarabine and present our approach to the use of nelarabine in the treatment of patients with T-ALL\/LBL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010303","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T11:14:17Z","timestamp":1688123657000},"page":"23-36","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-9652","authenticated-orcid":false,"given":"Shai","family":"Shimony","sequence":"first","affiliation":[{"name":"1Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Department of Hematology, Rabin Medical Center and Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":false,"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"1Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4529","authenticated-orcid":false,"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[{"name":"1Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,27]]},"reference":[{"issue":"20","key":"2024010913084739400_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"16","key":"2024010913084739400_bib2","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1056\/NEJM197504172921604","article-title":"Clinical importance of lymphoblasts with T markers in childhood acute leukemia","volume":"292","author":"Sen","year":"1975","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024010913084739400_bib3","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1002\/acg2.70","article-title":"T-cell acute lymphoblastic leukemia: current approach and future directions","volume":"2","author":"Luskin","year":"2019","journal-title":"Adv Cell Gene Ther"},{"issue":"3","key":"2024010913084739400_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood.2019001557","article-title":"How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children","volume":"135","author":"Teachey","year":"2020","journal-title":"Blood"},{"issue":"25","key":"2024010913084739400_bib5","first-page":"3019","article-title":"How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults","volume":"141","author":"Si Lim","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2024010913084739400_bib6","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1080\/10428194.2018.1522442","article-title":"Incidence and survival of T-cell acute lymphoblastic leukemia in the United States","volume":"60","author":"Guru Murthy","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2024010913084739400_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1182\/hematology.2022000337","article-title":"Optimal approach to T-cell ALL","volume":"2022","author":"O'Dwyer","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"25","key":"2024010913084739400_bib8","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","article-title":"T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL X2\/ECOG 2993)","volume":"114","author":"Marks","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2024010913084739400_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2024010913084739400_bib10","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1200\/JCO.2003.10.116","article-title":"Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium experience","volume":"21","author":"Goldberg","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"29","key":"2024010913084739400_bib11","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 Methotrexate Randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2024010913084739400_bib12","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1182\/blood.V99.12.4386","article-title":"Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL","volume":"99","author":"Willemse","year":"2002","journal-title":"Blood"},{"issue":"12","key":"2024010913084739400_bib13","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2024010913084739400_bib14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"issue":"19","key":"2024010913084739400_bib15","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1182\/blood-2011-02-334219","article-title":"Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1\/FBXW7 mutations, but not of low ERG\/BAALC expression: a GRAALL study","volume":"118","author":"Ben Abdelali","year":"2011","journal-title":"Blood"},{"issue":"17","key":"2024010913084739400_bib16","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1182\/blood-2008-10-184069","article-title":"NOTCH1\/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study","volume":"113","author":"Asnafi","year":"2009","journal-title":"Blood"},{"issue":"26","key":"2024010913084739400_bib17","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2009.22.0996","article-title":"Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII\/ECOG E2993 protocol","volume":"27","author":"Mansour","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"5694","key":"2024010913084739400_bib18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1102160","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng","year":"2004","journal-title":"Science"},{"issue":"4","key":"2024010913084739400_bib19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MOH.0b013e3283623c61","article-title":"Early T-cell precursor acute lymphoblastic leukaemia","volume":"20","author":"Haydu","year":"2013","journal-title":"Curr Opin Hematol"},{"issue":"23","key":"2024010913084739400_bib20","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1182\/blood-2012-11-465138","article-title":"Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations","volume":"121","author":"Neumann","year":"2013","journal-title":"Blood"},{"issue":"7380","key":"2024010913084739400_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","article-title":"The genetic basis of early T-cell precursor acute lymphoblastic leukaemia","volume":"481","author":"Zhang","year":"2012","journal-title":"Nature"},{"issue":"2","key":"2024010913084739400_bib22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"15","key":"2024010913084739400_bib23","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood-2015-08-661702","article-title":"Early T-cell precursor acute lymphoblastic leukemia\/lymphoma (ETP-ALL\/LBL) in adolescents and adults: a high-risk subtype","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2024010913084739400_bib24","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","article-title":"Early response-based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a group for Research on Adult Acute Lymphoblastic Leukemia Study","volume":"35","author":"Bond","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"2024010913084739400_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V124.21.1.1","article-title":"T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children\u2019s Oncology Group (COG) Study AALL0434","volume":"124","author":"Wood","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2024010913084739400_bib26","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2024010913084739400_bib27","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"2024010913084739400_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11899-019-00501-3","article-title":"Relapsed T cell ALL: current approaches and new directions","volume":"14","author":"McMahon","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"2024010913084739400_bib29","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2014-10-551895","article-title":"How I treat T-cell acute lymphoblastic leukemia in adults","volume":"126","author":"Litzow","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2024010913084739400_bib30","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2016-07-692608","article-title":"Management of adults with T-cell lymphoblastic leukemia","volume":"129","author":"Marks","year":"2017","journal-title":"Blood"},{"issue":"7914","key":"2024010913084739400_bib31","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0140-6736(75)91950-9","article-title":"Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity","volume":"1","author":"Giblett","year":"1975","journal-title":"Lancet"},{"issue":"5","key":"2024010913084739400_bib32","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1172\/JCI109058","article-title":"Deoxyguanosine triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency","volume":"61","author":"Cohen","year":"1978","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"2024010913084739400_bib33","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1073\/pnas.76.4.1998","article-title":"Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function","volume":"76","author":"Gelfand","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"2024010913084739400_bib34","first-page":"3352","article-title":"2-amino-6-methoxypurine arabinoside: an agent for T-cell malignancies","volume":"55","author":"Lambe","year":"1995","journal-title":"Cancer Res"},{"issue":"4","key":"2024010913084739400_bib35","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood.V61.4.660.660","article-title":"Selective toxicity of deoxyguanosine and arabinosyl guanine for T- leukemic cells","volume":"61","author":"Cohen","year":"1983","journal-title":"Blood"},{"issue":"3","key":"2024010913084739400_bib36","first-page":"1008","article-title":"Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts","volume":"45","author":"Shewach","year":"1985","journal-title":"Cancer Res"},{"issue":"3","key":"2024010913084739400_bib37","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1172\/JCI111514","article-title":"Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts","volume":"74","author":"Ullman","year":"1984","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"2024010913084739400_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1021\/bi00889a004","article-title":"Synthesis of 9-\u03b2-D-arabinofuranosylguanine","volume":"3","author":"Reist","year":"1964","journal-title":"Biochemistry"},{"issue":"12","key":"2024010913084739400_bib39","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1021\/bi00515a048","article-title":"Purine nucleoside synthesis: an efficient method employing nucleoside phosphorylases","volume":"20","author":"Krenitsky","year":"1981","journal-title":"Biochemistry"},{"issue":"8","key":"2024010913084739400_bib40","first-page":"3646","article-title":"Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts","volume":"45","author":"Verhoef","year":"1985","journal-title":"Cancer Res"},{"issue":"23","key":"2024010913084739400_bib41","first-page":"6498","article-title":"Differential metabolism of 9-beta-D-arabinofuranosylguanine in human leukemic cells","volume":"49","author":"Shewach","year":"1989","journal-title":"Cancer Res"},{"issue":"15","key":"2024010913084739400_bib42","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2005.03.199","article-title":"Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies","volume":"23","author":"Kurtzberg","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2024010913084739400_bib43","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2024010913084739400_bib44","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"issue":"13","key":"2024010913084739400_bib45","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1182\/blood-2011-01-329441","article-title":"High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation","volume":"118","author":"Gokbuget","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2024010913084739400_bib46","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ajh.25957","article-title":"Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed\/refractory T-cell acute lymphoblastic leukemia\/lymphoma. A CAMPUS ALL study","volume":"95","author":"Candoni","year":"2020","journal-title":"Am J Hematol"},{"issue":"6","key":"2024010913084739400_bib47","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2006-0017","article-title":"FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia\/lymphoma","volume":"13","author":"Cohen","year":"2008","journal-title":"Oncologist"},{"issue":"3","key":"2024010913084739400_bib48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2141.2010.08236.x","article-title":"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed\/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma","volume":"150","author":"Commander","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"2024010913084739400_bib49","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/bjh.13771","article-title":"Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma","volume":"174","author":"Luskin","year":"2016","journal-title":"Br J Haematol"},{"issue":"11","key":"2024010913084739400_bib50","doi-asserted-by":"crossref","first-page":"e29901","DOI":"10.1002\/pbc.29901","article-title":"Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR)","volume":"69","author":"Whitlock","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2024010913084739400_bib51","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/bloodadvances.2022008280","article-title":"Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma\/leukemia","volume":"7","author":"Shimony","year":"2023","journal-title":"Blood Adv"},{"issue":"22","key":"2024010913084739400_bib52","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.2011.40.8724","article-title":"Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"30","author":"Dunsmore","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2024010913084739400_bib53","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.20.00531","article-title":"Successful outcomes of newly diagnosed T lymphoblastic lymphoma: results from Children\u2019s Oncology Group AALL0434","volume":"38","author":"Hayashi","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"15 suppl","key":"2024010913084739400_bib54","doi-asserted-by":"crossref","first-page":"10500","DOI":"10.1200\/JCO.2018.36.15_suppl.10500","article-title":"COG AALL0434: a randomized trial testing nelarabine in newly diagnosed T-cell malignancy","volume":"36","author":"Dunsmore","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024010913084739400_bib55","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/pbc.25470","article-title":"Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434","volume":"62","author":"Winter","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"28","key":"2024010913084739400_bib56","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children's Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024010913084739400_bib57","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.20.02973","article-title":"Nelarabine in pediatric and young adult T-cell acute lymphoblastic leukemia-clearly beneficial?","volume":"39","author":"Agrawal","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2024010913084739400_bib58","doi-asserted-by":"crossref","first-page":"e29238","DOI":"10.1002\/pbc.29238","article-title":"A\u00a0new standard of care for childhood T-cell acute lymphoblastic leukemia?","volume":"68","author":"Gaynon","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"2024010913084739400_bib59","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2352-3026(23)00072-8","article-title":"Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group","volume":"10","author":"Sato","year":"2023","journal-title":"Lancet Haematol"},{"issue":"3","key":"2024010913084739400_bib60","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024010913084739400_bib61","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/leu.2013.312","article-title":"The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience","volume":"28","author":"Jain","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2024010913084739400_bib62","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.24947","article-title":"Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma","volume":"93","author":"Abaza","year":"2018","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2024010913084739400_bib63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood-2020-136873","article-title":"Frontline HCVAD with nelarabine and Peg-asparaginase in T-acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL): updated results of a phase II trial","volume":"136","author":"Maiti","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2024010913084739400_bib64","doi-asserted-by":"crossref","first-page":"11671","DOI":"10.1182\/blood-2022-159139","article-title":"Incorporation of nelarabine (NEL), pegylated asparaginase (PEG) and venetoclax (VEN) in the frontline therapy of adult patients with T-acute lymphoblastic leukemia\/T-lymphoblastic lymphoma (T-ALL\/LBL)","volume":"140","author":"Babakhanlou","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2024010913084739400_bib65","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/ajh.26144","article-title":"Outcome of T-cell acute lymphoblastic leukemia\/lymphoma: focus on near-ETP phenotype and differential impact of nelarabine","volume":"96","author":"Morita","year":"2021","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2024010913084739400_bib66","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2021-152355","article-title":"First analysis of the UKALL14 randomized trial to determine whether the addition of nelarabine to standard chemotherapy improves event free survival in adults with T-cell acute lymphoblastic leukaemia (CRUK\/09\/006)","volume":"138","author":"Rowntree","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024010913084739400_bib67","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood-2022-158381","article-title":"Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08\/2013 in 281 T-ALL \/ T-Lbl patients: excellent outcome of standard risk thymic T-ALL","volume":"140","author":"Goekbuget","year":"2022","journal-title":"Blood"},{"issue":"19","key":"2024010913084739400_bib68","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1200\/JCO.21.02678","article-title":"Children's Oncology Group Trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024010913084739400_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00172","article-title":"Venetoclax and bortezomib in relapsed\/refractory early T-cell precursor acute lymphoblastic leukemia","volume":"3","author":"La Starza","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"2024010913084739400_bib70","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"2024010913084739400_bib71","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","article-title":"BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia","volume":"111","author":"Del Gaizo Moore","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2024010913084739400_bib72","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","article-title":"BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells","volume":"75","author":"Alford","year":"2015","journal-title":"Cancer Res"},{"issue":"6","key":"2024010913084739400_bib73","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"issue":"4","key":"2024010913084739400_bib74","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","article-title":"Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia","volume":"20","author":"Richard-Carpentier","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"2024010913084739400_bib75","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2024010913084739400_bib76","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41375-019-0548-z","article-title":"Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell\/CD19\/CD22-negative acute lymphoblastic leukemia","volume":"34","author":"Ofran","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"2024010913084739400_bib77","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3324\/haematol.2021.279851","article-title":"Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study","volume":"107","author":"Cerrano","year":"2022","journal-title":"Haematologica"},{"issue":"16 suppl","key":"2024010913084739400_bib78","doi-asserted-by":"crossref","first-page":"10001","DOI":"10.1200\/JCO.2022.40.16_suppl.10001","article-title":"Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed\/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): results from the phase 2 DELPHINUS study","volume":"40","author":"Hogan","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"16 suppl","key":"2024010913084739400_bib79","doi-asserted-by":"crossref","first-page":"TPS7070","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7070","article-title":"A\u00a0phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed\/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"40","author":"Guru Murthy","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024010913084739400_bib80","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2024010913084739400_bib81","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"2024010913084739400_bib82","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1078-0432.CCR-20-1271","article-title":"Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2024010913084739400_bib83","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1182\/blood-2022-158878","article-title":"Analysis of 53 patients with relapsed or refractory (R\/R) T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) treated with CD7-targeted CAR-T cell therapy","volume":"140","author":"Zhang","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024010913084739400_bib84","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-020-00187-x","article-title":"Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia","volume":"9","author":"Zheng","year":"2020","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"2024010913084739400_bib85","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1182\/blood-2008-02-138172","article-title":"NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity","volume":"113","author":"Armstrong","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2024010913084739400_bib86","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood.V84.9.3122.3122","article-title":"Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86","volume":"84","author":"Reiter","year":"1994","journal-title":"Blood"},{"issue":"4","key":"2024010913084739400_bib87","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S2352-3026(22)00038-2","article-title":"Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial","volume":"9","author":"Marks","year":"2022","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"2024010913084739400_bib88","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2021-146306","article-title":"First results of the Risk-Adapted, MRD-Stratified GMALL Trial 08\/2013 in 705 adults with newly diagnosed acute lymphoblastic leukemia\/lymphoma (ALL\/LBL)","volume":"138","author":"Goekbuget","year":"2021","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/23\/2180431\/blooda_adv-2023-010303-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/1\/23\/2180431\/blooda_adv-2023-010303-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T08:09:31Z","timestamp":1704787771000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/1\/23\/496638\/Nelarabine-when-and-how-to-use-in-the-treatment-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,27]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010303","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,27]]}}}